NOVN.SW
$121.44
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally.
Intraday
Recent News
Sector Update: Health Care Stocks Advance Late Afternoon
Health care stocks rose late Monday afternoon, with the NYSE Health Care Index up 0.8% and the State
Julius Baer’s $30 Million Pay Package Shows the Price of a Banking Reset
The Swiss private bank paid its new boss more than UBS chief Sergio Ermotti, highlighting how costly it can be to rebuild credibility after a major scandal
FDA Approves NVS' Cosentyx in Hidradenitis Suppurativa for Adolescents
Novartis wins FDA nod to expand Cosentyx use to teens with hidradenitis suppurativa, making it the only IL-17A inhibitor for this group.
Will GILD's Move to Acquire ACLX Boost Its Cell Therapy Franchise?
Gilead plans a $7.8B Arcellx acquisition as cell therapy sales decline, seeking full control of anito-cel to strengthen its oncology pipeline.
Assessing Novartis (SWX:NOVN) Valuation After Recent Mixed Share Price Performance
Novartis (SWX:NOVN) has drawn fresh attention after recent share price moves, with the stock showing mixed short term returns but a stronger result over the past 3 months and year. See our latest analysis for Novartis. Recent trading has been softer, with a 7 day share price return of 3.19% and a 30 day share price return of a 0.13% decline. However, the 90 day share price return of 14.54% and 1 year total shareholder return of 28.46% indicate that momentum has been building over a longer...